DK2207568T3 - Antistoffer specifikke for den protofibrile form af beta-amyloid-protein - Google Patents
Antistoffer specifikke for den protofibrile form af beta-amyloid-protein Download PDFInfo
- Publication number
- DK2207568T3 DK2207568T3 DK08849467.9T DK08849467T DK2207568T3 DK 2207568 T3 DK2207568 T3 DK 2207568T3 DK 08849467 T DK08849467 T DK 08849467T DK 2207568 T3 DK2207568 T3 DK 2207568T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- seq
- monoclonal antibody
- val
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
Claims (26)
1. Isoleret monoklonalt antistof, der specifikt interagerer og har en affinitet på mindst 106 M'1 som målt med overfladeplasmonresonans for en konformationel epitop af en protofibril form af Αβ-peptid, hvorved den protofibrile epitop repræsenteres afen eksponeret region afen Αβ-protofibril form omfattende aminosyresekvensen som fremsat i SEQ ID NO: 3, yderligere omfattende en variabel letkæde omfattende en CDRl-region som fremsat i SEQ ID NO: 13, en CDR2-region som fremsat i SEQ ID NO: 14, og en CDR3 som fremsat i SEQ ID NO: 15, og en variabel tungkæde omfattet af en CDRl-region som fremsat i SEQ ID NO:20, en CDR2-region som fremsat i SEQ ID NO:21, og en CDR3 som fremsat i SEQ ID NO:22.
2. Det isolerede monoklonale antistof ifølge krav 1, hvor den eksponerede region yderligere omfatter aminosyresekvensen som fremsat i SEQ ID NO:4.
3. Det monoklonale antistof ifølge krav 1 eller 2, hvilket er produceret af en hybridom tilgængelig under ATCC accessionsnummer PTA-8830.
4. Det monoklonale antistof ifølge krav 1 eller 2, yderligere omfattende en variable letkæde omfattet af aminosyresekvensen som fremsat i SEQ ID NO:5, og en variabel tungkæde omfattet af aminosyresekvensen som fremsat i SEQ ID NO:7.
5. Det monoklonale antistof ifølge et hvilket som helst af kravene 1-4, hvor antistoffet er et humaniseret monoklonalt antistof.
6. Det monoklonale antistof ifølge et hvilket som helst af kravene 1-5, hvor antistoffet er et humant monoklonalt antistof.
7. Fremgangsmåde til fremstilling af et monoklonalt antistof ifølge et hvilket som helst af kravene 1-6, omfattende: (a) at immunisere et ikke-humant pattedyr med den protofibrile form af β-amyloidpeptidet; (b) at høste B-celler fra pattedyret; (c) at skabe hybridomer fra de høstede B-celler, hvor hybridomerne producerer antistoffer; og, (d) at vælge hybridomer, der producerer antistoffer, der specifikt binder til den protofibrile form af β-amyloidpeptid, samtidig med at de har minimal affinitet for monomere eller dimere former af β-amyloidpeptid.
8. Fremgangsmåde til at kvantificere mængden af en protofibril form af β-amyloidpeptid i en vævs- eller fluidprøve, omfattende: (a) at opnå vævs- eller fluidprøven fra et individ; (b) at bringe vævs- eller fluidprøven i kontakt med et monoklonalt antistof ifølge et hvilket som helst af kravene 1-6 eller fragment deraf, der specifikt binder til den protofibrile form af β-amyloidpeptid, samtidig med at have minimal affinitet for former af β-amyloidpeptid med lav molekylevægt; og, (c) at kvantificere mængden af protofibril form af β-amyloidpeptid i prøven.
9. Kit til at detektere protofibril form af β-amyloidpeptid samtidig med at have større affinitet for en protofibril form af β-amyloidpeptid end til en form af β-amyloidpeptid med lav molekylevægt, omfattende: (a) et monoklonalt antistof ifølge et hvilket som helst af kravene 1-6 eller et fragment deraf, i stand til specifikt at binde in vitro til en gentagen konformationel epitop afen protofibril form af β-amyloidpeptid samtidig med at have minimal affinitet til former af β-amyloidpeptid med lav molekylevægt; og, (b) en reagent, der binder, direkte eller indirekte, til antistoffet eller fragmentet deraf.
10. Farmaceutisk sammensætning omfattende (i) et monoklonalt antistof af et variabelt regionfragment deraf ifølge et hvilket som helst af kravene 1-6, der specifikt interagerer med den protofibril lære form af Αβ-amyloid, og (ii) en farmaceutisk acceptabel bærer, hvor den specifikke interaktion er kendetegnet ved et forhold mellem affiniteten af et variabelt regionfragment af antistoffet for den protofibril lære Αβ-form og affiniteten for andre Αβ-former på større end omkring 2.
11. Den farmaceutiske sammensætning ifølge krav 11, hvor antistoffet er et monoklonalt antistof.
12. Den farmaceutiske sammensætning ifølge krav 10, fremgangsmåden ifølge krav 7, eller kittet ifølge krav 9, hvor antistoffet er fremstillet af et hybridom tilgængeligt under ATCC Accessionsnummer PTA-8830.
13. Den farmaceutiske sammensætning ifølge krav 11, hvor det monoklonale antistof er et humaniseret monoklonalt antistof eller et humant monoklonalt antistof.
14. Hybridom tilgængeligt under ATCC Accessionsnummer PTA-8830.
15. Isoleret nukleinsyremolekyle, der koder for antistoffet ifølge et hvilket som helst af kravene 1-6, hvor det variable tungkædefragment omfatter aminosyresekvensen som fremsat i SEQ ID NO:7.
16. Isoleret nukleinsyremolekyle, der koder for antistoffet ifølge et hvilket som helst af kravene 1-6, hvor nukleinsyremolekylet omfatter nukleotidsekvensen som fremsat i SEQ ID NO:8.
17. Ekspressionsvektor til ekspressionen af antistoffet ifølge et hvilket som helst af kravene 1-6, i en rekombinant værtscelle, hvor ekspressionsvektoren indeholder nukleinsyremolekylet ifølge krav 15 eller 16.
18. Kultiveret værtscelle, der udtrykker antistoffet ifølge et hvilket som helst af kravene 1-6, hvor værtscellen indeholder ekspressionsvektoren ifølge krav 17.
19. Isoleret nukleinsyremolekyle, der koder for antistoffet ifølge et hvilket som helst af kravene 1-6, hvor det variable letkædefragment omfatter aminosyresekvensen som fremsat i SEQ ID NO:5.
20. Isoleret nukleinsyremolekyle, der koder for antistoffet ifølge et hvilket som helst af kravene 1-6, hvor nukleinsyremolekylet omfatter nukleotidsekvensen som fremsat i SEQ ID NO:6.
21. Ekspressionsvektor til ekspressionen af antistoffet ifølge et hvilket som helst af kravene 1-6, i en rekombinant værtscelle, hvor ekspressionsvektoren indeholder nukleinsyremolekylet ifølge krav 19 eller 20.
22. Kultiveret værtscelle, der udtrykker antistoffet ifølge et hvilket som helst af kravene 1-6, hvor værtscellen indeholder ekspressionsvektoren ifølge krav 21.
23. Monoklonalt antistof ifølge et hvilket som helst af kravene 1-6 eller et variabelt regionfragment deraf, til anvendelse i en behandling afen tilstand kendetegnet ved dannelse og deponering af β-amyloid-fiberplaques.
24. Farmaceutisk effektiv mængde af et monoklonalt antistof eller et antigenbindende fragment deraf ifølge et hvilket som helst af kravene 1-6 til anvendelse i behandling og/eller forebyggelse af beta-amyloid-plaque deponering associeret med begyndelsen og progressionen af Alzheimers sygdom.
25. Monoklonalt antistof ifølge et hvilket som helst af kravene 1-6 eller et antigenbindende fragment deraf til anvendelse i behandling af Alzheimers sygdom.
26. Monoklonalt antistof ifølge et hvilket som helst af kravene 1-6 eller et antigenbindende fragment deraf, til anvendelse i inhibition af dannelse og deponering af β-amyloid-fiberplaques.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98848107P | 2007-11-16 | 2007-11-16 | |
| US1974708P | 2008-01-08 | 2008-01-08 | |
| PCT/US2008/083659 WO2009065054A2 (en) | 2007-11-16 | 2008-11-14 | Antibodies specific for the protofibril form of beta-amyloid protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2207568T3 true DK2207568T3 (da) | 2017-09-18 |
Family
ID=40639468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08849467.9T DK2207568T3 (da) | 2007-11-16 | 2008-11-14 | Antistoffer specifikke for den protofibrile form af beta-amyloid-protein |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US8470321B2 (da) |
| EP (2) | EP2207568B1 (da) |
| JP (3) | JP5616230B2 (da) |
| KR (3) | KR101478995B1 (da) |
| CN (1) | CN102006887B (da) |
| AU (1) | AU2008322523B2 (da) |
| BR (1) | BRPI0819312A2 (da) |
| CA (1) | CA2705582A1 (da) |
| CO (1) | CO6270277A2 (da) |
| CR (1) | CR11350A (da) |
| CY (1) | CY1119376T1 (da) |
| DK (1) | DK2207568T3 (da) |
| DO (1) | DOP2010000097A (da) |
| EA (1) | EA201000809A1 (da) |
| ES (1) | ES2639016T3 (da) |
| HK (1) | HK1244823A1 (da) |
| HR (1) | HRP20171292T1 (da) |
| HU (1) | HUE033825T2 (da) |
| IL (1) | IL204542A (da) |
| LT (1) | LT2207568T (da) |
| MA (1) | MA31890B1 (da) |
| ME (1) | ME01026B (da) |
| MX (2) | MX335965B (da) |
| MY (1) | MY158903A (da) |
| NI (1) | NI201000046A (da) |
| NZ (1) | NZ583632A (da) |
| PL (1) | PL2207568T3 (da) |
| PT (1) | PT2207568T (da) |
| SG (1) | SG2014011183A (da) |
| SI (1) | SI2207568T1 (da) |
| TN (1) | TN2010000128A1 (da) |
| WO (1) | WO2009065054A2 (da) |
| ZA (1) | ZA201002592B (da) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| PT2099826E (pt) * | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anticorpo anti-beta-amilóide e suas utilizações |
| EA201000809A1 (ru) | 2007-11-16 | 2010-12-30 | Те Рокфеллер Юниверсити | АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА |
| MX2011006422A (es) | 2008-12-19 | 2011-09-15 | Panima Pharmaceuticals Ag | Autoanticuerpos humanos anti-alfa-sinucleina. |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| ES2864049T3 (es) * | 2009-06-29 | 2021-10-13 | Bioarctic Ab | Anticuerpos selectivos para protofibrillas/oligómeros de amiloide-P truncado en el extremo N |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| US9498519B2 (en) | 2010-07-23 | 2016-11-22 | Gwangju Institute Of Science And Technology | Amyloid-beta clearance |
| CA2817973C (en) * | 2010-10-15 | 2019-06-25 | The Board Of Regents Of The University Of Texas System | Antibodies that bind amyloid oligomers |
| AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| EA030777B9 (ru) | 2011-06-23 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Анти-альфа-синуклеинсвязывающие молекулы |
| WO2013075740A1 (en) | 2011-11-23 | 2013-05-30 | Sanofi | Antibody purification method |
| JP2013159596A (ja) * | 2012-02-08 | 2013-08-19 | Nihon Univ | β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体 |
| US9617332B2 (en) * | 2012-05-10 | 2017-04-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Conformational-specific antibodies against A[β] oligomers |
| EP2674495A1 (en) | 2012-06-14 | 2013-12-18 | Sanofi | CHO expression system |
| BR112015027812B1 (pt) | 2013-05-06 | 2021-03-30 | Sanofi | Método para a purificação de uma proteína a partir de uma solução |
| WO2015051159A1 (en) * | 2013-10-02 | 2015-04-09 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| SI3166970T1 (sl) * | 2014-07-10 | 2021-09-30 | Bioarctic Ab | Izboljšana A-beta protofibril vezavna protitelesa |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN108350051A (zh) * | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | 淀粉样蛋白β中的N-末端表位及其构象选择性抗体 |
| CN108350050A (zh) * | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | 淀粉样蛋白β中的表位及其构象选择性抗体 |
| EP3374383A4 (en) * | 2015-11-09 | 2019-05-15 | The University Of British Columbia | BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES |
| KR20180085736A (ko) | 2015-11-09 | 2018-07-27 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체 |
| DE102016005169B3 (de) * | 2016-04-29 | 2017-07-13 | Forschungszentrum Jülich GmbH | Verfahren zur Identifikation von Inhibitoren der primären Nukleation der Amyloid-Beta-Aggregation |
| KR102550991B1 (ko) * | 2016-07-18 | 2023-07-04 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에 대한 항체 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| EP3354278A1 (en) * | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| IL272773B2 (en) | 2017-08-22 | 2024-06-01 | Biogen Ma Inc | Pharmaceutical preparations containing anti-amyloid cell antibodies |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| AU2018349387B2 (en) * | 2017-10-12 | 2022-05-19 | E&S Healthcare Co., Ltd. | Thioredoxin 1 epitope and monoclonal antibody specifically binding thereto |
| EP3801618A4 (en) * | 2018-05-30 | 2022-07-27 | National Health Research Institutes | ANTI-ABETA ANTIBODIES AND USES THEREOF |
| CA3124790A1 (en) | 2019-01-09 | 2020-07-16 | Vect-Horus | Transferrin receptor-binding molecules, conjugates thereof and their uses |
| TW202110878A (zh) | 2019-05-16 | 2021-03-16 | 法商賽諾菲公司 | 在神經系統中表現抗原結合蛋白 |
| JPWO2021006212A1 (da) * | 2019-07-08 | 2021-01-14 | ||
| IL300059A (en) | 2020-07-23 | 2023-03-01 | Othair Prothena Ltd | Anti-Abata antibodies |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2023034324A2 (en) * | 2021-08-30 | 2023-03-09 | The Brigham And Women’S Hospital, Inc. | Methods and materials to treat neurodegenerative disease |
| KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4636524A (en) | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP1649850A1 (en) | 1993-11-19 | 2006-04-26 | Alkermes Controlled Therapeutics Inc. II | Preparation of biodegradable microparticles containing a biologically active agent |
| WO1998043089A1 (en) | 1997-03-03 | 1998-10-01 | Bristol-Myers Squibb Company | Monoclonal antibodies to human cd6 |
| US6656508B2 (en) | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
| ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
| WO1999024061A1 (en) | 1997-11-07 | 1999-05-20 | Chiron Corporation | Method for producing igf-1 sustained-release formulations |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| US6451346B1 (en) | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
| DE60044057D1 (de) * | 1999-09-03 | 2010-05-06 | Univ Ramot | Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung |
| US6953593B2 (en) | 2000-02-01 | 2005-10-11 | Lipoprotein Technologies, Inc. | Sustained-release microencapsulated delivery system |
| CN101670105B (zh) * | 2000-02-24 | 2014-08-06 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
| NZ521939A (en) | 2000-05-22 | 2004-04-30 | Univ New York | Inducing an immune response to amyloid beta peptides and amyloid deposits using a synthetic non-amylogenic but immunogenic peptide |
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| WO2002053739A2 (en) * | 2000-11-15 | 2002-07-11 | Zymogenetics, Inc. | Neuropilin homolog zcub5 |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| CA2444569C (en) | 2001-04-18 | 2011-01-04 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
| EA011853B1 (ru) * | 2002-03-13 | 2009-06-30 | Байоджен Айдек Ма Инк. | АНТИТЕЛА ПРОТИВ αβ |
| US8420353B2 (en) | 2002-03-22 | 2013-04-16 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| DE60336848D1 (de) * | 2002-09-12 | 2011-06-01 | Univ California | Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz |
| WO2005025516A2 (en) * | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
| US7063725B2 (en) | 2002-10-21 | 2006-06-20 | Sdgi Holdings, Inc. | Systems and techniques for restoring and maintaining intervertebral anatomy |
| US20040223970A1 (en) * | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
| US20050124016A1 (en) * | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
| CA2437639C (en) | 2003-08-11 | 2016-07-05 | Valera Pharmaceuticals, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
| US20050187631A1 (en) | 2004-01-27 | 2005-08-25 | Sdgi Holdings, Inc. | Prosthetic device |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US20110020237A1 (en) | 2005-01-14 | 2011-01-27 | Glabe Charles G | Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| EP1937720B1 (en) | 2005-08-18 | 2014-04-09 | Ramot at Tel-Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
| KR20140087058A (ko) * | 2005-11-30 | 2014-07-08 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| RU2429244C2 (ru) * | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| JP2010530744A (ja) | 2007-06-12 | 2010-09-16 | エーシー イミューン ソシエテ アノニム | アミロイドβに対するヒト化抗体 |
| EA201000809A1 (ru) | 2007-11-16 | 2010-12-30 | Те Рокфеллер Юниверсити | АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
-
2008
- 2008-11-14 EA EA201000809A patent/EA201000809A1/ru unknown
- 2008-11-14 KR KR1020137010598A patent/KR101478995B1/ko active IP Right Grant
- 2008-11-14 KR KR1020147029636A patent/KR101581733B1/ko active IP Right Grant
- 2008-11-14 DK DK08849467.9T patent/DK2207568T3/da active
- 2008-11-14 BR BRPI0819312-6A patent/BRPI0819312A2/pt not_active Application Discontinuation
- 2008-11-14 CA CA2705582A patent/CA2705582A1/en not_active Abandoned
- 2008-11-14 CN CN200880116438.9A patent/CN102006887B/zh not_active Expired - Fee Related
- 2008-11-14 LT LTEP08849467.9T patent/LT2207568T/lt unknown
- 2008-11-14 KR KR1020107011148A patent/KR101377535B1/ko active IP Right Grant
- 2008-11-14 JP JP2010534239A patent/JP5616230B2/ja not_active Expired - Fee Related
- 2008-11-14 MY MYPI2010001497A patent/MY158903A/en unknown
- 2008-11-14 SI SI200831857T patent/SI2207568T1/sl unknown
- 2008-11-14 HU HUE08849467A patent/HUE033825T2/en unknown
- 2008-11-14 MX MX2012010835A patent/MX335965B/es unknown
- 2008-11-14 EP EP08849467.9A patent/EP2207568B1/en not_active Not-in-force
- 2008-11-14 US US12/738,955 patent/US8470321B2/en not_active Expired - Fee Related
- 2008-11-14 AU AU2008322523A patent/AU2008322523B2/en not_active Ceased
- 2008-11-14 NZ NZ583632A patent/NZ583632A/en not_active IP Right Cessation
- 2008-11-14 MX MX2010003828A patent/MX2010003828A/es active IP Right Grant
- 2008-11-14 PT PT88494679T patent/PT2207568T/pt unknown
- 2008-11-14 WO PCT/US2008/083659 patent/WO2009065054A2/en active Application Filing
- 2008-11-14 ES ES08849467.9T patent/ES2639016T3/es active Active
- 2008-11-14 PL PL08849467T patent/PL2207568T3/pl unknown
- 2008-11-14 ME MEP-2010-76A patent/ME01026B/me unknown
- 2008-11-14 EP EP17173145.8A patent/EP3257865A1/en not_active Withdrawn
- 2008-11-14 SG SG2014011183A patent/SG2014011183A/en unknown
-
2010
- 2010-03-16 IL IL204542A patent/IL204542A/en active IP Right Grant
- 2010-03-22 TN TNP2010000128A patent/TN2010000128A1/fr unknown
- 2010-04-07 NI NI201000046A patent/NI201000046A/es unknown
- 2010-04-07 CR CR11350A patent/CR11350A/es unknown
- 2010-04-07 DO DO2010000097A patent/DOP2010000097A/es unknown
- 2010-04-07 CO CO10039830A patent/CO6270277A2/es not_active Application Discontinuation
- 2010-04-14 ZA ZA2010/02592A patent/ZA201002592B/en unknown
- 2010-05-17 MA MA32845A patent/MA31890B1/fr unknown
-
2011
- 2011-01-21 HK HK18104106.3A patent/HK1244823A1/zh unknown
-
2013
- 2013-05-28 US US13/903,081 patent/US9340607B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 JP JP2014135187A patent/JP2014223074A/ja active Pending
-
2016
- 2016-05-16 US US15/155,275 patent/US20160319006A1/en not_active Abandoned
-
2017
- 2017-08-28 HR HRP20171292TT patent/HRP20171292T1/hr unknown
- 2017-08-30 CY CY20171100918T patent/CY1119376T1/el unknown
-
2018
- 2018-03-22 JP JP2018054674A patent/JP2018140988A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2207568T3 (da) | Antistoffer specifikke for den protofibrile form af beta-amyloid-protein | |
| JP7061875B2 (ja) | アミロイドベータタンパク質に対するモノクローナル抗体及びその使用 | |
| TWI557136B (zh) | 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途 | |
| MXPA04008740A (es) | Anticuerpos humanizados que reconocen el peptido amiloide beta. | |
| US11161898B2 (en) | Anti-amyloid-beta antibodies | |
| TWI508976B (zh) | 對β－類澱粉蛋白之基原纖維形式具專一性之抗體 | |
| OA19316A (en) | Antibodies specific for the protofibril form of beta-amyloid protein |